Painful diabetic neuropathy (PDN) is estimated to affect 16% of the more than 25 million people who have diabetes in this country. Unfortunately, the condition is often unreported and untreated.
The American Academy of Neurology (AAN) released new guidelines on the treatment of PDN, providing physicians with evidence-based management on use of various pharmacologic agents (ie, anticonvulsants, antidepressants, and opioids) as well as nonpharmacologic treatment (ie, transcutaneous electrical nerve stimulation and magnetic field treatment).
Click below for a snapshot of the strong evidence (Level A) and moderate evidence (Level B) recommendations that were in the guidelines released by the AAN:
